Search

Given the development of drug-resistant cancer cells, designing alternative approaches for cancer treatment seems essential. In this study, we evaluated the anti-tumor effects of nisin A and Newcastle disease virus (NDV) on triple-negative MDA-MB-231 cell line. The MDA-MB-231 cell line was separately and in combination subjected to the different concentrations of a Veroadapted NDV (JF820294.1) and nisin A. The oncolytic effects of these treatments were analyzed by different cytotoxic and apoptosis techniques including trypan blue staining, MTT assay, acridine orange (EB/AO) staining, colony assay and flow cytometry over time. Nisin A at doses of more than 20.00 μg mL-1 could represent the anti-viral effects and interfere with the oncolytic activity of NDV. Moreover, the analyses indicated that the anti-proliferative and cytotoxic features of combination therapy were stronger than those of individual NDV groups. However, the most apoptotic effect was seen in NDV experimental groups. Taken together, the results from cytotoxicity tests, flow cytometry and colony assay showed that either of the oncolytic agents had significant effects at low concentrations 72 hr post-treatment. Thereby, they had the potential to be used as new approaches in cancer treatment. [ABSTRACT FROM AUTHOR]

Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological events, such as migration and activation. Owing to this fact, angiogenesis blockade therapy was established to fight cancer by eliminating the nutrient and oxygen supply to the malignant cells by impairing the vascular network. Given the dominant role of vascular-endothelium growth factor (VEGF) in the angiogenesis process, the well-known anti-angiogenic agents mainly depend on the targeting of its actions. However, cancer cells mainly show resistance to anti-angiogenic agents by several mechanisms, and also potentiated local invasiveness and also distant metastasis have been observed following their administration. Herein, we will focus on clinical developments of angiogenesis blockade therapy, more particular, in combination with other conventional treatments, such as immunotherapy, chemoradiotherapy, targeted therapy, and also cancer vaccines. 64SciJHJrfLYaKT285oK4U Video abstract [ABSTRACT FROM AUTHOR]

[Display omitted] • Synthesis of Tetraphenylporphyrin and H2T(4-SO2Cl)PP. • Conjugation of functionalized porphyrin to albumin-metronidazole nanoparticles. • In vitro radiation/photodynamic therapy. Breast cancer is the second leading cause of cancer death in women after lung cancer. In the context of cancer therapy, chemotherapy regarded as the most common method of treatment, but besides this beneficial modality, radiation therapy (RT) is used as a supplementary or palliative treatments. In this regard, we aimed at preparing albumin- Tetraphenylporphyrin -metronidazole nanosystem (BSA-Met- H2T(4-SO2)PP NPs) as an effective photo/radiosensitizer along with RT to tackle breast cancer. Accordingly, the synthesized nanosystems were analyzed by various characterization techniques such as dynamic light scattering (DLS), fourier transform infrared spectroscopy (FT-IR), UV–vis, and proton nuclear magnetic resonance (1HNMR), also transmission electron microscopy (TEM) technique was used to determine the morphology and size of fabricated nanosystems. Moreover, the biosafety of developed nanosystems were ascertained using LD 50 and hemolysis assay. Based on DLS measurements the average size and polydispersity index of fabricated nanosystems were about 190 nm and 0.36, respectively. The BSA-Met-H2T(4-SO2)PP NPs showed pH-dependent drug release behavior. The results showed that the drug loading (DL) for metronidazole and Tetraphenylporphyrin were 3.406% and 13.586%, respectively. Both hemolysis and LD 50 confirmed the biosafety of the BSA-Met-H2T(4-SO2)PP NPs. Finally, MTT assay revealed that the prepared nanoparticles exhibited great anti-cancer activity upon radiation and light against 4 T1 cancer cells. Overall, our findings suggest that PPHN-MET NPs may be promising candidates for the effective radiation/or light-induced cancer therapy. [ABSTRACT FROM AUTHOR]

The transcription factor high mobility group protein A2 (HMGA2) plays an important role in the pathogenesis of some cancers including breast cancer. Polyamidoamine dendrimer generation 4 is a kind of highly branched polymeric nanoparticle with surface charge and highest density peripheral groups that allow ligands or therapeutic agents to attach it, thereby facilitating target delivery. Here, methotrexate (MTX)- modified polyamidoamine dendrimer generation 4 (G4) (G4/MTX) was generated to deliver specific small interface RNA (siRNA) for suppressing HMGA2 expression and the consequent effects on folate receptor (FR) expressing human breast cancer cell lines (MCF-7, MDA-MB-231). We observed that HMGA2 siRNA was electrostatically adsorbed on the surface of the G4/MTX nanocarrier for constructing a G4/MTX-siRNA nano-complex which was verified by changing the final particle size and zeta potential. The release of MTX and siRNA from synthesized nanocomplexes was found in a time- and pH-dependent manner. We know that MTX targets FR. Interestingly, G4/MTX-siRNA demonstrates significant cellular internalization and gene silencing efficacy when compared to the control. Besides, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay demonstrated selective cell cytotoxicity depending on the FR expressing in a dose-dependent manner. The gene silencing and protein downregulation of HMGA2 by G4/MTX-siRNA was observed and could significantly induce cell apoptosis in MCF-7 and MDA-MB-231 cancer cells compared to the control group. Based on the findings, we suggest that the newly developed G4/MTX-siRNA nano-complex may be a promising strategy to increase apoptosis induction through HMGA2 suppression as a therapeutic target in human breast cancer. [ABSTRACT FROM AUTHOR]

[Display omitted] • BSA coated Pt nanoparticles was applied as both radiosensitizer and drug carrier. • In terms of morphology, nanoparticles appeared to be homogenous and monodispersed. • The results disclosed that designed nanoplatform due to the presence of Pt and BSA had ability to kill cancer cells effectively. Bovine serum albumin (BSA) coated platinum (Pt) nanoparticles (Pt@BSA NPs) were synthesized, followed by the conjugation of an anticancer drug (MTX) with the aim of chemoradiation therapy. The physical and chemical properties of Pt@BSA-MTX were evaluated by DLS, FESEM, STEM, UV–Vis and XRD. A release study was performed in the presence and absence of the proteinase K enzyme. In terms of morphology, nanoparticles appeared to be monodispersed and spherical. The size of nanoparticles was 7.4 ± 1.4 nm. Release behavior of Pt@BSA-MTX depended significantly on enzyme presence which accelerated and promoted the release of MTX. The improved chemoradiation was demonstrated in vitro using MTT, colony formation and apoptosis assays on mouse breast carcinoma cells (4T1). It was concluded that the combination of a nanoradiosensitizer with a chemotherapeutic agent resulted in superior anticancer activity after X-ray exposure. [ABSTRACT FROM AUTHOR]